Company: SXTPW
Filing Date: 2025-07-16
Form Type: 424B4
Source: 0001213900-25-064472
Chunk: 6

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-07-16
Form: 424B4
Chunk 6
---
 have been issued pursuant to any warrants or options, including the Warrants and the Placement Agent Warrants. |

<div align='center'>TRADEMARKS</div>

Solely for convenience, our trademarks and tradenames
referred to in this prospectus, may appear without the ® or ™ symbols, but such references are not intended to indicate in any
way that we will not assert, to the fullest extent under applicable law, our rights to these trademarks and tradenames. All other trademarks,
service marks and trade names included or incorporated by reference into this prospectus or the accompanying prospectus are the property
of their respective owners.

<div align='center'>GLOSSARY OF SELECTED TERMS</div>

The following are definitions of certain terms
that are commonly used in the medical industry and in this prospectus:

| ● | “API” means active                                                                    
 pharmaceutical ingredient, the active molecule contained in a pharmaceutical product. |

| ● | “Arakoda” means ARAKODA®,                                                                                                                   
 the 60P-owned and FDA-approved product to prevent malaria in travelers, which contains as its active pharmaceutical ingredient, Tafenoquine 
 succinate.                                                                                                                                  |

| ● | “Broad Spectrum of Activity”                                                        
 refers to a molecule or drug that is active against a range of different pathogens. |

<div align='center'>ii</div>

| ● | “Dengue” means a mosquito-borne                            
 viral disease occurring in tropical and subtropical areas. |

| ● | “EUA” means Emergency 
 Use Authorization.    |

| ● | “FDA” refers to the                
 U.S. Food and Drug Administration. |

| ● | “G6PD” means glucose-6-phosphate 
 dehydrogenase.                   |

| ● | “Kodatef” is the brand                                                                                                             
 name of Arakoda outside the United States. Kodatef has been approved for use in Australia by the Therapeutic Goods Administration. |

| ● | “Legacy Studies” is                                                                                                                          
 a reference to the collection of clinical and non-clinical studies involving Tafenoquine, which were conducted by the U.S. Army prior        
 to 2014, and which were included in the new drug application submitted by 60P to the FDA in 2018. Some of those Legacy Studies are described 
 in the account of the Army development program published by Zottig et. al.                                                                   |

| ● | “Mode of Action” is                                                                                                                    
 the process by